NEW YORK (GenomeWeb News) – Autogenomics today said that it has received regulatory approval in Canada to market its Infiniti Pharmacogenomic testing system.

The Vista, Calif.-based firm received Health Canada Medical Device Class III approvals for the system along with two thrombolytic drug metabolism test kits, one for warfarin sensitivity and the other a 2C19 assay that indicates how a patient will metabolize commonly prescribed drugs.

The system and tests will be distributed in Canada by ESBE Scientific to labs providing clinical molecular testing services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.